Prothena Corp Public Ltd Co has disclosed notable stock transactions involving William P. Scully, a ten percent owner of the company. The recent filings reveal that Scully acquired a total of 150,000 shares over two days, which indicates a strong commitment to the company and may impact investor sentiment.
Prothena, which operates in the pharmaceutical preparations sector, is listed on the Nasdaq under the ticker symbol PRTA. The company, incorporated in Dublin, Ireland, has been actively managing its share structure, as evidenced by multiple recent filings, including Form 4 submissions.
According to the latest filing dated October 26, 2026, Scully purchased 100,000 shares on October 22 at an average price of $8.1852 and an additional 50,000 shares on October 23 at an average price of $8.0705. Following these transactions, Scully now holds a total of 1,187,000 shares in Prothena. The filing specifically notes that the reported prices are weighted averages from multiple transactions, with the exact prices ranging from $8.0600 to $8.2800 for the first transaction and $7.9884 to $8.1500 for the second.
This activity may affect various stakeholders, including current shareholders and potential investors, as it demonstrates confidence from a significant owner in the company’s future. Additionally, the filing indicates that Scully's spouse and an investment fund, Manatee Equity Fund LLC, also hold shares, suggesting a broader network of investment interest in Prothena.
As of now, the filing does not specify any immediate next steps or additional actions following these transactions. However, continued monitoring of insider trading activity may provide insights into the company's strategic direction and market performance.